These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20885926)

  • 61. Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells.
    Naitoh K; Kamigaki T; Matsuda E; Ibe H; Okada S; Oguma E; Kinoshita Y; Takimoto R; Makita K; Ogasawara S; Goto S
    Anticancer Res; 2016 Jul; 36(7):3715-24. PubMed ID: 27354645
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
    Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
    J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
    Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
    Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.
    Szender JB; Eng KH; Matsuzaki J; Miliotto A; Gnjatic S; Tsuji T; Odunsi K
    Gynecol Oncol; 2016 Jul; 142(1):158-162. PubMed ID: 27103177
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor antigens and markers for breast and ovarian cancers.
    Ghadersohi A; Chitta K; Greco WR; Harvey S; Winston J; Slocum H; Odunsi K; Sood AK
    Front Biosci; 2002 Feb; 7():e48-57. PubMed ID: 11815284
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The immunopeptidomic landscape of ovarian carcinomas.
    Schuster H; Peper JK; Bösmüller HC; Röhle K; Backert L; Bilich T; Ney B; Löffler MW; Kowalewski DJ; Trautwein N; Rabsteyn A; Engler T; Braun S; Haen SP; Walz JS; Schmid-Horch B; Brucker SY; Wallwiener D; Kohlbacher O; Fend F; Rammensee HG; Stevanović S; Staebler A; Wagner P
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E9942-E9951. PubMed ID: 29093164
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
    Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
    Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma.
    Qian X; Xi X; Li L
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):126-32. PubMed ID: 20724919
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
    Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
    Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
    Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.
    Esfandiary A; Ghafouri-Fard S
    Immunotherapy; 2015; 7(4):411-39. PubMed ID: 25917631
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
    Hylander B; Repasky E; Shrikant P; Intengan M; Beck A; Driscoll D; Singhal P; Lele S; Odunsi K
    Gynecol Oncol; 2006 Apr; 101(1):12-7. PubMed ID: 16263157
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Cancer antigen WT1-targeting treatment for the malignancies].
    Oka Y; Kawase I
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells.
    Li FQ; Han YL; Liu Q; Wu B; Huang WB; Zeng SY
    BMC Cancer; 2009 Sep; 9():323. PubMed ID: 19744347
    [TBL] [Abstract][Full Text] [Related]  

  • 77. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
    Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
    J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
    Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
    J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
    Wada H; Sato E; Uenaka A; Isobe M; Kawabata R; Nakamura Y; Iwae S; Yonezawa K; Yamasaki M; Miyata H; Doki Y; Shiku H; Jungbluth AA; Ritter G; Murphy R; Hoffman EW; Old LJ; Monden M; Nakayama E
    Int J Cancer; 2008 Nov; 123(10):2362-9. PubMed ID: 18729190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.